---
schema_version: "secwatch.filing_event.v1"
accession: "0001607062-21-000512"
form_type: "8-K"
ticker: "RGBP"
cik: "0001589150"
company_name: "Regen BioPharma Inc"
filed_at: "2021-11-12T23:59:59+00:00"
generated_at: "2026-06-28T09:13:07.304140+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Regen Biopharma signs non-binding LOI to acquire 95% of Canary Oncoceutics for $1M cash and stock

## Summary
- Consideration: $1,000,000 cash plus common shares valued at RGBP's average share price pre-closing.
- Closing contingent on raising $50,000,000 solely for Canary diagnostics and product development.
- Milestone payments up to $10,000,000 per test product, including $3M upon FDA approval.
- Earned royalty on net sales: 2.5% up to $250M, 4% up to $500M, 5% above $500M.
- IP licensed from Cornell University enables patient-derived tumor vascular nets for drug testing.

## SEC filing metadata
- accession: 0001607062-21-000512
- form_type: 8-K
- ticker: RGBP
- cik: 0001589150
- company_name: Regen BioPharma Inc
- filed_at: 2021-11-12T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1589150/000160706221000512/0001607062-21-000512-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1589150/000160706221000512/rgbp111221form8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001607062-21-000512
- JSON: https://secwatch.observer/filing/0001607062-21-000512.json
- Plain text: https://secwatch.observer/filing/0001607062-21-000512.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.